Anne Nagengast Johnson - Mar 13, 2024 Form 4 Insider Report for ATAI Life Sciences N.V. (ATAI)

Role
Chief Financial Officer
Signature
/s/ Ryan Barrett , Attorney-in-fact
Stock symbol
ATAI
Transactions as of
Mar 13, 2024
Transactions value $
$0
Form type
4
Date filed
3/15/2024, 08:16 PM
Previous filing
May 19, 2023
Next filing
Apr 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATAI Common Shares Options Exercise +100K +10000% 101K Mar 14, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATAI Stock Option Award $0 +550K $0.00 550K Mar 13, 2024 Common Shares 550K $1.84 Direct F2
transaction ATAI Restricted Stock Units Options Exercise $0 -100K -50% $0.00 100K Mar 14, 2024 Common Shares 100K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one common share of the Issuer upon vesting and settlement. 50% of the restricted stock units will vest on the first anniversary of the grant date and 50% will vest on the second anniversary of the grant date.
F2 The stock option shall vest as to 25% of the underlying shares on January 1, 2025, and in 36 substantially equal monthly installments thereafter.